Capricor Stock Jumps 14% as HOPE-3 Poster Opens at WMS
Capricor Therapeutics (CAPR) stock rose 13.54% to $9.73 in pre-market trading as its HOPE-3 poster on Deramiocel was presented at the World Muscle Society congress. The poster covers 24-month data, including a delayed-start analysis and natural-history comparison. Capricor previously submitted these analyses to the FDA as part of a major amendment to its BLA, pushing the PDUFA date to Nov. 22, 2026.
How this was made
The 30-second read
Why it matters
The pre‑market price jump reflects market anticipation of positive efficacy signals, but FDA review remains uncertain.
Market read
A biotech micro‑cap experienced a double‑digit pre‑market rally on fresh clinical data exposure, offering a short‑term trading opportunity.
What to watch
Potential FDA skepticism after the advisory committee vote against cardiomyopathy indication.
Background
Capricor Therapeutics is a biotech developing Deramiocel for Duchenne muscular dystrophy; the HOPE‑3 trial is a pivotal study.
Ticker impact
Capricor shares jumped 13.5% in pre‑market trading after the HOPE‑3 poster opened at the World Muscle Society congress.
likely continued upward pressure as investors digest the delayed‑start and natural‑history results.
The move is a direct reaction to fresh trial data exposure; similar biotech catalysts have produced short‑term price gains.
Market effects
May lift sentiment for other rare‑disease gene‑therapy stocks.
Limited to US biotech investors.
Low; impact confined to niche therapeutic sector.
Counterpoint
The poster data may not translate to regulatory approval, so the rally could be short‑lived.
Key entities
- companyCapricor Therapeutics Inc.
Developer of Deramiocel, subject of the HOPE‑3 trial.
- organizationWorld Muscle Society (WMS)
Host of the virtual congress where the poster was released.
